Your browser doesn't support javascript.
loading
Analysis of Factors Influencing Clinical Efficacy of Rituximab on Patients with Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma / 中国实验血液学杂志
Journal of Experimental Hematology ; (6): 1210-1214, 2020.
Artigo em Chinês | WPRIM | ID: wpr-827138
ABSTRACT
OBJECTIVE@#To analyze the clinical efficacy and safety of rituximab therapy for patients with Epstein-Barr virus (EBV) positive diffuse large B-cell lymphoma (DLBCL), and to explore the factors influencing the clinical efficacy.@*METHODS@#According to therapeutic regimen, 66 patients with EBV-positive DLBCL were divided into two groups CHOP group (32 cases) and R-CHOP group (CHOP+ rituximab, 34 cases). The clinical efficacy and the incidence of complication were compared between two groups. The clinical risk factors for the clinical efficacy in patients with EBV-positive DLBCL were confirmed by multivariate Logistic analysis.@*RESULTS@#Compared with CHOP group, the complete remission rate, partial remission rate and the overall effective rate in R-CHOP group all were high (P<0.05), moreover the disease progression rate in R-CHOP group were low (P<0.05). The occurrences rate of myelotoxicity, hepatic injury and gastrointestinal reaction were not statistically significantly different between two groups (P>0.05). Multivariate Logistic analysis showed that the Ann Arbor staging, IPI risk score and Ki-67 positive rate were independent risk factors for the clinical efficacy in patients with EBV-positive DLBCL (OR=2.689, P=0.038; OR=3.232, P=0.025; OR=2.919, P=0.023).@*CONCLUSION@#The clinical efficacy and safety of the therapy with rituximab on the patients with EBV-positive DLBCL are better. The poor Ann Arbor stage, high IPI risk score and the Ki-67 positive rate are factors affecting the clinical efficacy for the patients with EBV-positive DLBCL.
Assuntos
Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Vincristina / Prednisona / Protocolos de Quimioterapia Combinada Antineoplásica / Doxorrubicina / Linfoma Difuso de Grandes Células B / Resultado do Tratamento / Herpesvirus Humano 4 / Ciclofosfamida / Usos Terapêuticos / Tratamento Farmacológico Tipo de estudo: Fatores de risco Limite: Humanos Idioma: Chinês Revista: Journal of Experimental Hematology Ano de publicação: 2020 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Vincristina / Prednisona / Protocolos de Quimioterapia Combinada Antineoplásica / Doxorrubicina / Linfoma Difuso de Grandes Células B / Resultado do Tratamento / Herpesvirus Humano 4 / Ciclofosfamida / Usos Terapêuticos / Tratamento Farmacológico Tipo de estudo: Fatores de risco Limite: Humanos Idioma: Chinês Revista: Journal of Experimental Hematology Ano de publicação: 2020 Tipo de documento: Artigo